Concentra delivered a clean second-quarter print as a fully independent public company. The print confirmed the operating leverage thesis that management built into the post-Select Medical separation completed in late 2024. Total revenue reached $606.0 million in the quarter against $550.8 million a year earlier. Adjusted EBITDA reached $140.9 million against $115.0 million. Net leverage ended the quarter at 2.99x, comfortably inside the credit-agreement covenant. The combination of double-digit revenue growth and sharply higher profitability provides a strong base for the leadership handoff that takes effect late this year. The Q2 2026 print arrives at a meaningful inflection point in the standalone trajectory, with the Pivot Onsite acquisition delivering a fresh growth engine and the leadership transition introducing an executive refresh that the post-separation board has spent years preparing. The pivot from Select Medical subsidiary to independent public operator completed eighteen months ago, and the Q2 print is now the cleanest read on the standalone operating profile. Investors who focus on the multi-quarter setup rather than any single quarter can anchor on the raised full-year guidance as the operative forward-looking signal.
The capital-return machinery ran on schedule during the quarter. Free cash flow reached $121.0 million, up 91.6% year over year. Diluted earnings per share of $0.51 represented a $0.16 improvement over the prior-year result. Cumulative share repurchases reached $25.9 million against the $54.1 million of remaining authorization. The insider repurchase of one million shares from chairman Robert Ortenzio extended the buyback runway. The leadership transition is the second governance inflection in eighteen months for the standalone company. The cadence of capital returns, including the recurring $0.0625 per share quarterly dividend, signals management's confidence in the multi-year cash-generation trajectory. The combination of buybacks plus dividends creates a predictable shareholder yield that anchors the equity story while the operating leverage provides the upside.
The strategic question for the next four quarters is whether Concentra can absorb the leadership transition without disrupting operating momentum. The company enters the back half of the year with raised full-year revenue guidance. Adjusted EBITDA guidance now sits at $485 million to $495 million. Net leverage guidance of below 3.0x establishes the balance-sheet constraint. Free cash flow guidance of $220 million to $240 million establishes the cash-generation guardrails. Investors should watch Adjusted EBITDA margin, where the recent print reached a new standalone high. The pivot from Select Medical subsidiary to independent operator is now structurally complete. The next several quarters test whether the operating playbook can survive the executive refresh. The combination of guidance raise, leadership continuity from the outgoing CEO, and fresh capital structure creates a multi-quarter setup that the post-separation board has been engineering since the distribution completed in September 2024. Patience is required from investors who view the leadership transition as an execution risk rather than an event-driven disruption. The strategic question for the next four quarters resolves through three observable inputs: execution against the raised guidance range, the cadence of capital returns, and the post-transition board composition.